Recce Pharma's R327 Defeats Multidrug-Resistant Superbug

Recce Pharmaceuticals Ltd. has reported promising outcomes from a study indicating that its drug, RECCE 327 (R327), effectively eradicates the multidrug-resistant 'superbug' Acinetobacter baumannii. The research demonstrated that R327 achieved a reduction in bacterial presence by over 99.99999% within one hour of administration and sustained its effectiveness for 24 hours, surpassing the performance of the conventional antibiotic ciprofloxacin. These results highlight R327's potential as a robust treatment option for severe infections, including those resistant to multiple drugs.